Pulling SEC filings + quote and writing the call…

enGene Therapeutics Inc.
Next earnings Sep 9, 2026 · consensus $-0.51 EPS
Last earnings +9.3% on 2026-06-15
Conservative balance sheet (liabilities/equity 0.32x).
Sources: SEC EDGAR (CIK 0001980845, latest 10-Q filed 2026-06-15) · EODHD · as of 6/25/2026, 8:56:51 AM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.
Middling fundamentals offset by an attractive price (~895% below fair value) — worth a look on the value angle.
enGene Therapeutics Inc. shows limited reported revenue, and -69.9% ROE.
The risks, catalysts, 12-month price target and the cited SEC figures behind this rating — with Pro.
Unlock with Pro€15/mo · cancel anytime
| Line item | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|
| Revenue | — | — | — | — |
| Gross profit | — | — | — | — |
| Operating income | -$19.4M | -$26.1M | -$62.3M | -$123M |
| Net income | -$24.5M | -$99.9M | -$55.1M | -$117M |
| Diluted EPS | $44.30 | $151.22 | $1.46 | $2.29 |
| Net margin | — | — | — | — |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
1079 tracked peers · median
Dates from 8-K (Item 2.02); beat/miss = reported EPS vs consensus (Finnhub, recent quarters); move = prior close → close on/after.
Recent news tone vs the market's typical (which skews positive). A soft signal, not a recommendation.